The search for optimal decision in the treatment of multiple sclerosis: to improve adherence not reducing the efficacy

Popova, E. V.; Novikova, K V; Хачанова, Н. В.; Konovalova, O E; Kozhieva, M Kh; Davydovskaya, M. V.; Boyko, A. N.

doi:10.17116/jnevro201711710248-52

Z. nevrol. psikhiatr. im. S.S. Korsakova

2017

DOI: 10.17116/jnevro201711710248-52

|View full text |Cite

The search for optimal decision in the treatment of multiple sclerosis: to improve adherence not reducing the efficacy

E. V. Popova¹,

K V Novikova²,

Н. В. Хачанова³

et al.

Abstract: Long-term disease modifying therapy (DMD) therapy is the basis of modern MS treatment, effiecacy of which is modulated by the patient's adherence to therapy. One of the possible solutions of low adherence improvement is the use of innovative drugs and the development of more convenient regimens of injectable medications. This article gives a brief review of peg-interferon β-1a clinical trials.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2021

2024

Publication Types

Select...

Article4

Relationship

Self Cite1

Independent3

Authors

Journals

Cited by 4 publications

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Clinical and epidemiological characteristics of multiple sclerosis in students in the Republic of Bashkortostan

Tukhvatullin

Kuzmina

Utyagulova

et al. 2021

RJTAO

View full text Add to dashboard Cite

An expansion of the age range of multiple sclerosis (MS) manifestation has been reported recently. Considering the multifactorial etiology, high heterogeneity of the clinical symptoms, and the difficulties of early MS diagnosis in young people, the onset and course of this disease in students can be considered as one of the significant medical and social problems.Objective: to analyze the clinical and epidemiological characteristics of MS in university and secondary specialized educational institutions students in the Republic of Bashkortostan (RB).Patients and methods. This case-control study included 32 patients aged 15 to 24 years studying in universities and secondary schools of the RB. The clinical and epidemiological indicators analysis was carried out based on data from the register of MS patients in the RB. 32 sex-, age-, place of birth and residence-matching patients with MS, who were not students, were included in the control group.Results and discussion. The median age of disease manifestation in students was 18 [16.5; 20] years, in the control group – 16 [14; 19] years (p=0.010). We found a lower «disease onset – diagnosis» in the students group of revealed a lower interval «disease onset – diagnosis» (0.5 [0; 1] years, p=0.006), and a shorter duration of MS compared to the control group ((2.8 [2; 4] years and 4 [2; 7] years, respectively, p=0.020). Students with MS predominantly had movement disorders: central paresis and cerebellar ataxia. Students also had a faster MS progression (0.4 [0.2; 0.6] EDSS scores per year, p=0.001), despite of the disease-modifying therapies.Conclusion. MS manifestation and course in students receiving disease-modifying therapies indicate the need for close follow-up, adherence control, and psychological support in the educational process.

show abstract

Clinical and epidemiological characteristics of multiple sclerosis in students in the Republic of Bashkortostan

Tukhvatullin

Kuzmina

Utyagulova

et al. 2021

RJTAO

View full text Add to dashboard Cite

show abstract

Ways to improve adherence to long-term injection therapy in multiple sclerosis using the example of pegylated interferon-β1a (sampeginterferon β-1a)

Boyko

2022

RJTAO

Self Cite

View full text Add to dashboard Cite

Patient adherence to therapy with multiple sclerosis disease-modifying treatments (MS DMTs) in many cases determine the effectiveness of therapy. The review discusses the reasons for low adherence to DMTs, ways to increase it. Among the most effective ways is to reduce the frequency of administration of the drug while maintaining its high efficiency. To illustrate this, the increase in adherence to treatment with interferon-β drugs due to pegylation is discussed. Without losing its effectiveness, sampeginterferon beta-1a (samPEG-IFN-β1a) administration reduces the frequency of local adverse reactions, partly due to reducing the frequency of injections, which contributes to higher adherence to the treatment.

show abstract

Adherence to treatment in the management of patients with multiple sclerosis

Shaglaeva,

Titova,

Pashkovskaya

et al. 2024

S.S. Korsakov J. Neuro. Psych.

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

The search for optimal decision in the treatment of multiple sclerosis: to improve adherence not reducing the efficacy

Cited by 4 publications

References 32 publications

Clinical and epidemiological characteristics of multiple sclerosis in students in the Republic of Bashkortostan

Clinical and epidemiological characteristics of multiple sclerosis in students in the Republic of Bashkortostan

Ways to improve adherence to long-term injection therapy in multiple sclerosis using the example of pegylated interferon-β1a (sampeginterferon β-1a)

Adherence to treatment in the management of patients with multiple sclerosis

Contact Info

Product

Resources

About